| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| ln Vitro |
Indusatumab vedotin (0.4-25 μg/mL; 72 hours) can exert an antiproliferative effect on pancreatic cancer cell lines[1]. Indusatumab vedotin (12.5 μg/mL; 24 hours) can arrest the cell cycle of MIA PaCa-2 and PANC-1 cells in the G2/M phase and induce the production of phosphorylated histone H3[1].
|
|---|---|
| ln Vivo |
Indusatumab vedotin (10 mg/kg; intravenous injection; once a week for at least 17 days) significantly reduced tumor growth rate[1]. In mice carrying six different xenograft models, the bioactivity of indusatumab vedotin was closely related to drug exposure[2].
|
| Cell Assay |
Western Blot Analysis [1]
Cell Types: MIA PaCa-2 and PANC-1 cells Tested Concentrations: 12.5 μg/mL Incubation Duration: 24 hours Experimental Results: Increased protein levels of P-histone H3 indicated microtubule polymerization. Cell cycle analysis [1] Cell Types: MIA PaCa-2 and PANC-1 cells Tested Concentrations: 12.5 μg/mL Incubation Duration: 24 hours Experimental Results: The number of cells in the G1 phase decreased, leading to G2/M phase arrest. Western Blot Analysis [1] Cell Types: GCC knockout cells and pancreatic cancer cell lines: L3.6, MIA PaCa-2, Panc 03.27, Panc 05.04 and Panc 02.03 Test concentrations: 0.4 μg/mL, 0.8 μg/mL, 1.6 μg/mL, 3.1 μg/mL, 6.3 μg/mL, 12.5 μg/mL and 25 μg/mL Incubation Duration: 72 hours Experimental Results: Inhibited the cell viability of pancreatic cancer cells, but had no effect on GCC knockout cells. |
| Animal Protocol |
Animal/Disease Models:Mouse pancreatic explant xenograft model [1]
Doses: 10 mg/kg Route of Administration: Tail vein injection; once a week for 17-50 days Experimental Results: Significantly inhibited the growth of 10 types of tumors. |
| References |
|
| CAS # |
1514889-12-3
|
|---|---|
| Appearance |
Colorless to light yellow liquid
|
| SMILES |
[Indusatumab vedotin]
|
| Synonyms |
MLN0264; TAK-264
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
